Condition
Consolidation Therapy
Total Trials
4
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Recruiting3
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07425782Phase 2Recruiting
Venetoclax Combined With Azacitidine for Consolidation Therapy in AML
NCT07672262Phase 2Recruiting
VA Consolidation in Intermediate-Risk AML
NCT07563907Not ApplicableNot Yet Recruiting
Total Neoadjuvant Therapy With Additional Consolidation Chemotherapy Followed by Local Excision Versus Total Neoadjuvant Therapy Followed by Local Excision at Stage I Rectal Cancer
NCT07086456Phase 2Recruiting
Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung Cancer
Showing all 4 trials